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Introduction: Serious non-AIDS events (SNAE) are frequent in HIV patients receiving cART. Current CD4 count was shown to be
more strongly associated with infective compared to not-infective SNAE and unable to predict cardiovascular events. We
investigated the relationship between baseline and current CD4 count and the risk of both infective and non-infective SNAE in
HIV-positive patients according to current ART use.
Methods: We included all HIV-positive persons enrolled in the ICONA Foundation Study cohort who had at least one follow-up
visit. SNAE were grouped in infective (pneumonia, sepsis, endocarditis and meningitis) and non-infective (malignancies, chronic
kidney disease, cardiovascular events, hepatic events and pancreatitis) aetiology. Incidence of these event groups were
calculated overall and according to baseline and current CD4 count (grouped as 0200, 201350, 351500, 501750, and 750
cells/mm3). Participants’ follow-up accrued from the date of enrolment (baseline) to a diagnosis of SNAE or their last visit. An
event was defined the first time one of the considered SNAE occurred so that each person contributed a single event. A Poisson
regression model for each of the two endpoints was used.
Results: A total of 10,822 patients were included (25.3% females, 38.2% heterosexuals) and 26.6% had hepatitis co-infections.
Median age was 36 (IQR 3142) years. Overall, 423 not-infective and 385 infective SNAE were included. The most frequent non-
infective SNAE were malignancies (n202) and the most frequent infective SNAE were pneumonia (n289). Crude rates of
non-infective SNAE were 0.78, 1.08 and 0.80/100 PYFU, and those of infective SNAE were 1.00, 0.51 and 0.66/100 PYFU in ART
naive, currently off and currently on ART patients, respectively. Higher current CD4 count was associated with reduced risk of
both infective and non-infective SNAE in naives and in patients on ART (Table 1). The association was less strong in the group
which suspended ART (for non-infective SNAE the p value for interaction between current log-CD4 and ART-status, p0.004).
Conversely, we found no association between baseline CD4 count and risk of non-infective SNAE in people treated with ART (p
value for interaction0.0001). When CVD were considered separately, there was no association with CD4 count (not shown).
Conclusions: Our findings show that, differently from ART naive, in ART-treated patients, non-infective SNAE are predicted by
current but not by baseline CD4, suggesting that immune restoration is crucial to prevent these events.
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Table 1. Adjusted rate ratios (ARR) of infective and non-infective serious non-AIDS events (SNAE) from fitting Poisson regression
models
Infective SNAE
Non-infective
SNAE
ART naive Currently off ART Currently on ART ART naive Currently off ART Currently on ART
ARR (95% CI), p
value
ARR (95% CI), p
value
ARR (95% CI), p
value
ARR (95% CI), p
value
ARR (95% CI), p
value
ARR (95% CI), p
value
Current CD4 count
(cells/mmc)
5200 1.00 1.00 1.00 1.00 1.00 1.00
201350 0.19 (0.10, 0.34),
B0.001
1.00 (0.28, 3.55),
0.996
0.35 (0.23, 0.52),
B0.001
0.40 (0.20, 0.81),
0.011
0.90 (0.33, 2.47),
0.832
0.48 (0.32, 0.72),
B0.001
351500 0.11 (0.06, 0.20),
B0.001
0.38 (0.08, 1.83),
0.226
0.24 (0.16, 0.37),
B0.001
0.18 (0.09, 0.36),
B0.001
0.55 (0.19, 1.56),
0.258
0.56 (0.37, 0.84),
0.005
501750 0.08 (0.04, 0.16),
B0.001
0.10 (0.01, 0.86),
0.036
0.21 (0.13, 0.32),
B0.001
0.19 (0.10, 0.35),
B0.001
0.26 (0.07, 0.93),
0.027
0.47 (0.33, 0.71),
B0.001
750 0.11 (0.05, 0.22),
B0.001
0.20 (0.01, 2.06),
0.177
0.14 (0.08, 0.26),
B0.001
0.16 (0.07, 0.35),
B0.001
0.41 (0.11, 1.50),
0.176
0.32 (0.20, 0.52),
B0.001
Baseline CD4 count
(cells/mmc)
5200 1.00 1.00 1.00 1.00 1.00 1.00
201350 0.12 (0.05, 0.27),
B0.001
0.13 (0.02, 1.04),
0.055
0.59 (0.39, 0.88),
0.010
0.34 (0.15, 0.79),
0.012
0.78 (0.29, 2.09),
0.625
1.27 (0.91, 1.76),
0.154
351500 0.10 (0.05, 0.19),
B0.001
0.20 (0.05, 0.75),
0.017
0.53 (0.35, 0.80),
0.003
0.15 (0.07, 0.33),
B0.001
0.32 (0.12, 0.90),
0.031
0.89 (0.62, 1.27),
0.523
501750 0.09 (0.05, 0.16),
B0.001
0.07 (0.01, 0.58),
0.014
0.49 (0.31, 0.76),
0.002
0.16 (0.08, 0.32),
B0.001
0.36 (0.13, 1.01),
0.052
1.09 (0.76, 1.56),
0.643
750 0.07 (0.03, 0.14),
B0.001
0.44 (0.09, 2.08),
0.302
0.49 (0.24, 1.02),
0.055
0.21 (0.10, 0.42),
B0.001
0.29 (0.07, 1.20),
0.087
0.72 (0.38, 1.34),
0.298
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